Rumalon injection 1ml amp 25 pcs Rompharm

Description

Composition
Active substance:
Glycosaminoglycan-peptide complex.
Description:
The clear solution of pale yellow color with a brownish tint to yellowish brown with cresol smell.
Product form:
Solution for intramuscular administration. 1 ml or 2 ml glass ampoules of the light-shielding dark color with a white ring fracture. On each vial label paste. 5 ampoules per strip cellular polymeric packaging made of PVC-coated PET / PE foil. 1, 2 or 5 the contour of cellular packaging made of PVC, together with instructions for use placed into cardboard pack.
Contraindications
Hypersensitivity to the drug, rheumatoid arthritis, age 18 years, pregnancy, breast-feeding, the use in women of reproductive age who do not comply with reliable contraceptive methods.
Dosage
1 ml
Indications
Degenerative-dystrophic diseases of the joints: gonarthrosis, arthrosis of the interdigital joints, coxarthrosis, spondylosis, spondylarthritis, meniskopatiya, chondromalacia patella.
Interaction with other drugs
Rumalon® drug can be administered simultaneously with non-steroidal anti-inflammatory drugs and corticosteroids. In an application with indirect anticoagulants, antiplatelet and fibrinolytic agents may enhance their action.
Overdose
So far, cases of overdose have been reported.
pharmachologic effect
Pharmacodynamics:
Combined animal drug comprises a glycosaminoglycan-peptide complex. Effect of the drug due to the combined action of its active components. Normalizes metabolism in hyaline cartilage tissues: increases biosynthesis of sulfated mucopolysaccharides and collagen, stimulates the regeneration of articular cartilage, reducing the activity of enzymes and inhibits catabolic processes in the cartilage.
Pharmacokinetics:
Studies have not been conducted.
Pregnancy and breast-feeding
Use of the drug during pregnancy and breast-feeding period is contraindicated (due to lack of information on the use of the drug in these patients groups).
Conditions of supply of pharmacies
On prescription.
side effects
According to WHO undesirable effects are classified according to frequency of their development as follows: very often (> 1/10), often (by> 1/100 to
special instructions
While the use of indirect anticoagulants, antiplatelet and fibrinolytic agents requires frequent monitoring of blood coagulation parameters. Use of the drug has no effect on the ability to perform potentially hazardous activities that require high concentration and psychomotor speed reactions (vehicle control, work with moving machinery, the work manager and operator).
Storage conditions
At a temperature of not higher than 25 C and protected from light.
Keep out of the reach of children.
Dosing and Administration
The drug is administered by deep intramuscular injection: the first day – 0.3 ml on the second day – 0.5 ml and then 3 times a week for 1 ml for 5-6 weeks. Second course of treatment – after consulting a doctor in the same way.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist